This landmark direct-comparison trial confirmed that tirzepatide produced approximately 47% greater body weight reduction than semaglutide in adults with obesity over a comparable treatment period the first robust head-to-head evidence in patients without type 2 diabetes
But heres the catch: many believe these medications are a one-and-done solution
National Insurance Specialists offers employers a proprietary standalone GLP-1 and Tirzepatide program that offers significant benefits to employers at no cost
FAQ Wegovy, Zepbound, Saxenda, and Foundayo are approved to treat adults with a BMI of 30 or greater, or with a BMI of at least 27 and one weight-related condition, such as high blood pressure or high cholesterol
Varan HI, Dursun B, Dursun E, Ozben T, Suleymanlar G
It is a transformational experience that equips you with the mindset, discipline, and leadership identity required to lead with excellence